Talin-1 and Non-invasive Fibrosis Models in the Assessment of Patients with Hepatocellular Carcinoma

Background Hepatocellular carcinoma (HCC) is a dreadful complication of end stage liver disease with high morbidity and mortality. Aim The aim is to assess the role of serum talin-1 and non-invasive brosis in patients with HCC. Materials and Methods A total of eighty seven subjects were enrolled, 22 two healthy individuals as a control group (n22), 22 patients in the cirrhosis group and nally 43 in the group with HCC diagnosed with positive triphasic CT abdomen criteria. Serum talin-1 and noninvasive brosis parameters were assessed in all subjects. Results Compared to the cirrhosis group, patients with HCC had higher serum talin-1 (32.912.6 vs. 11.12.79 ng/ml), FIB4 (9.9615.3 vs. 2.901.87) and bro- (10.918.1 vs. 1.550.28) but not brosis index scores (4.470.95 vs. 4.980.96; p0.046). Patients with large focal lesions (5cm) had different ALBI scores (-1.020.63 vs. -1.720.59; p0.001) serum talin-1 (9.7213.81 vs. 28.638.89 ng/ml; p0.007) and brosis index scores (0.85 0.99 vs. 4.204.85; p0.026). No statistical differences were noted between patients with and without portal vein thrombosis. For detection of HCC, serum talin-1 had 97.7% sensitivity and 100% speci city with a 17.2 ng/ml cutoff. AFP at a 13.7 ng/ml cutoff had 72.1% sensitivity and 6.3.6% speci city. The cutoff for the bro- score was 1.61 with 81.4% sensitivity and 77.3% speci city. Serum talin-1 (odds1.08; C.I1.016-1.150; p0.014), brosis index score (odds2.35; C.I1.055-5.217; p0.037) and the ALBI score (odds6.9; C.I1.924-24.708; p0.003) were predictors of large focal lesions. Conclusions Serum talin-1, AST/ALT ratio, bro- score are useful for the assessment of HCC patients.